Below are the most recent publications written about "Protease Inhibitors" by people in Profiles.
-
Tobin NH, Murphy A, Li F, Brummel SS, Fowler MG, Mcintyre JA, Currier JS, Chipato T, Flynn PM, Gadama LA, Saidi F, Nakabiito C, Koos BJ, Aldrovandi GM. Metabolomic profiling of preterm birth in pregnant women living with HIV. Metabolomics. 2023 10 25; 19(11):91.
-
Cohen JD, Cziraky MJ, Jacobson TA, Maki KC, Karalis DG. Barriers to PCSK9 inhibitor prescriptions for patients with high cardiovascular risk: Results of a healthcare provider survey conducted by the National Lipid Association. J Clin Lipidol. 2017 Jul - Aug; 11(4):891-900.
-
Mo H, Hedskog C, Lawitz E, Brainard DM, Yang J, Delaney W, Worth A, Miller MD. Antiviral response and resistance analysis of treatment-na?ve HCV infected patients receiving multiple doses of the NS3 protease inhibitor GS-9256. Antiviral Res. 2017 04; 140:151-157.
-
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.
-
Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother. 2014; 58(2):647-53.
-
Lawitz EJ, Hill JM, Marbury T, Demicco MP, Delaney W, Yang J, Moorehead L, Mathias A, Mo H, McHutchison JG, Rodriguez-Torres M, Gordon SC. A Phase I, randomized, placebo-controlled, 3-day, ascending-dose study of GS-9451, an NS3/4A protease inhibitor, in genotype 1 hepatitis C patients. Antivir Ther. 2013; 18(3):311-9.
-
Schultz B, Yang H, Delaney WE. Biochemical evaluation of HCV NS3 protease inhibitors. Curr Protoc Pharmacol. 2011 Sep; Chapter 13:Unit13B.7.
-
Argiris A, Duffy AG, Kummar S, Simone NL, Arai Y, Kim SW, Rudy SF, Kannabiran VR, Yang X, Jang M, Chen Z, Suksta N, Cooley-Zgela T, Ramanand SG, Ahsan A, Nyati MK, Wright JJ, Van Waes C. Early tumor progression associated with enhanced EGFR signaling with bortezomib, cetuximab, and radiotherapy for head and neck cancer. Clin Cancer Res. 2011 Sep 1; 17(17):5755-64.
-
Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother. 2011 May; 55(5):2197-205.
-
Colella R, Lu G, Glazewski L, Korant B, Matlapudi A, England MR, Craft C, Frantz CN, Mason RW. Induction of cell death in neuroblastoma by inhibition of cathepsins B and L. Cancer Lett. 2010 Aug 28; 294(2):195-203.